Lymphoma Clinical Trials

Showing 621-640 of 2,926 trials

Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

NCT04961515

This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.

Primary Central Nervous System Hodgkin Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang University19 participantsStarted Jul 2021

Hangzhou, Zhejiang, China

RECRUITINGPhase 1/2

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

NCT07097207

1. Study Title: A Study on the Efficacy and Safety of Autocrine p40 CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cells (CD19/CD20-CAR.p40-T) in Relapsed/Refractory B-Cell Lymphoma 2. Study Objectives: * Primary Objective: To evaluate the safety of CD19/CD20 dual-targeting CAR.p40-T cell therapy in patients with relapsed/refractory B-cell lymphoma. * Secondary Objective: To evaluate the efficacy of CD19/CD20 dual-targeting CAR.p40-T cell therapy in patients with relapsed/refractory B-cell lymphoma. 3. Participant Intervention: * Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20-CAR.p40-T cell infusion or CD19 CAR.p40-T cell infusion. The CAR-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.

Relapsed/Refractory B-cell Lymphoma

Shenzhen University General Hospital20 participantsStarted Oct 2023

Shenzhen, Other (Non U.s.), China

COMPLETEDPhase 2

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

NCT03496779

This study is an open label, multicenter phase 2 study. The primary objective of the study is to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed after 4 cycles of treatment according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).

Refractory Peripheral T-Cell LymphomaRelapsed Peripheral T-Cell Lymphoma

The Lymphoma Academic Research Organisation71 participantsStarted Apr 2018

Antwerp, Belgium • Bruges, Belgium • Brussels, Belgium +36 more locations

Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Related Searches

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Living Conditions After Non-Hodgkin's Lymphoma in France

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma

PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

Haplo Peripheral Blood Sct In GVHD Prevention

Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies